altamira therapeutics (former auris medical) is dedicated to developing therapeutics that address important unmet medical needs. the company is currently active in three areas: • the development of rna therapeutics for extrahepatic therapeutic targets (oligophore™ / semaphore™ platforms; preclinical), • nasal sprays for protection against airborne viruses and allergens (bentrio™; commercial) or the treatment of vertigo (am-125; phase 2) • the development of therapeutics for intratympanic treatment of tinnitus or hearing loss (keyzilen® and sonsuvi®, phase 3). the company was founded in 2003, under the name auris medical, and is headquartered in hamilton, bermuda with its main operations in basel, switzerland. the shares of altamira therapeutics ltd. trade on the nasdaq capital market under the symbol “cyto.”
Company profile
Ticker
CYTO
Exchange
Website
CEO
Thomas Meyer
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Auris Medical AG, Auris Medical Holding AG, Auris Medical Holding Ltd.
SEC CIK
CYTO stock data
Latest filings (excl ownership)
424B4
Prospectus supplement with pricing info
22 Jan 24
EFFECT
Notice of effectiveness
22 Jan 24
6-K
Report of Foreign Private Issuer
19 Jan 24
424B5
Prospectus supplement for primary offering
19 Jan 24
6-K
Report of Foreign Private Issuer
19 Jan 24
CORRESP
Correspondence with SEC
17 Jan 24
UPLOAD
Letter from SEC
16 Jan 24
F-3
Shelf registration (foreign)
8 Jan 24
6-K
Altamira Therapeutics Provides Investor and Business Update
11 Dec 23
6-K
Report of Foreign Private Issuer
11 Dec 23
Latest ownership filings
SC 13D/A
Meyer Thomas
13 Mar 24
SC 13D/A
Meyer Thomas
27 Apr 23
SC 13D/A
Meyer Thomas
18 Jan 23
SC 13D/A
Meyer Thomas
13 Sep 22
SC 13D/A
Meyer Thomas
13 May 22
SC 13D/A
Meyer Thomas
21 May 21
SC 13G/A
Altium Capital Management LP
12 Feb 21
SC 13D/A
Meyer Thomas
7 Dec 20
SC 13D/A
Meyer Thomas
6 Oct 20
SC 13D/A
Meyer Thomas
20 Aug 20
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2023
5.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 5 |
Opened positions | 3 |
Closed positions | 4 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 47.27 mm |
Total shares | 73.74 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Citadel Advisors | 72.93 k | $46.75 mm |
MS Morgan Stanley | 500.00 | $321.00 k |
Group One Trading | 298.00 | $191.00 k |
Cutler | 10.00 | $0.00 |
Stonebridge Capital Advisors | 5.00 | $6.00 k |
Proequities | 0.00 | $0.00 |
News
Nasdaq Turns Higher; Akanda Shares Plunge
25 Mar 24
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
25 Mar 24
12 Health Care Stocks Moving In Monday's Intraday Session
25 Mar 24
Crude Oil Moves Higher; US New Home Sales Fall In February
25 Mar 24
Why Altamira Therapeutics Stock Is Racing Higher
25 Mar 24
Press releases
Thinking about buying stock in Equillium, Kuke Music, Altamira Therapeutics, MoneyHero, or Enerplus?
26 Mar 24
Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines
25 Mar 24
Altamira Therapeutics' Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal
7 Feb 24
Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment
24 Jan 24
Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit
8 Jan 24